Mostrar el registro sencillo del ítem

dc.contributor.authorAlvaro-Meca, Alejandro
dc.contributor.authorJiménez-Garcia, Rodrigo
dc.contributor.authorJimenez-Trujillo, Isabel
dc.contributor.authorHernandez-Barrera, Valentin
dc.contributor.authorde Miguel-Diez, Javier
dc.contributor.authorResino, Salvador 
dc.contributor.authorLopez-de-Andres, Ana
dc.date.accessioned2018-12-05T18:58:47Z
dc.date.available2018-12-05T18:58:47Z
dc.date.issued2016
dc.identifier.citationPLoS One. 2016 Sep 2;11(9):e0161953.es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6772
dc.description.abstractOBJECTIVE: To describe trends in the prevalence of diabetes among hospitalized HIV-infected patients between 1997 and 2012 in Spain and compare them with those of age- and sex-matched non-HIV-infected patients. METHODS: The study was based on Spanish national hospital discharge data. We performed a retrospective study for the period 1997-2012. HIV infection (HIV-infected versus non-HIV-infected [control group])and calendar period in relation to widespread use of combination antiretroviral therapy (cART) (1997-1999; 2000-2003; 2004-2007 and 2008-2012), were the exposure variables The outcome variables were diagnosis of diabetes and in-hospital mortality (IHM). RESULTS: From 1997 to 2012, we identified 91,752 cases of diabetes: 15,398 in the HIV-infected group (403,277 hospital admissions) and 76,354 in the non-HIV-infected group (1,503,467 hospital admissions). Overall, HIV-infected patients had lower prevalence values for diabetes than non-HIV-infected patients throughout the follow-up (3.8% vs. 5.1%; p<0.001). The prevalence of diabetes increased 1.56-fold among non-HIV-infected patients and 4.2-fold among HIV-infected patients. The prevalence of diabetes in females was almost twice as high in HIV-infected patients as in non-HIV-infected patients during the last study period (4.72% vs. 2.88%; p<0.001). Diabetes showed a protective effect against IHM throughout the study period (aOR = 0.70; 95%CI, 0.65-0.75). CONCLUSIONS: During the cART era, the prevalence of diabetes has increased sharply among HIV-infected hospitalized patients compared with matched non-HIV-infected subjects. The prevalence of diabetes is rising very fast among HIV-infected women. Diabetes has a protective effect on IHM among HIV-infected patients. Nevertheless, our study has several limitations. No information is available in the database used on important sociodemographic characteristics and relevant clinical variables including duration of the HIV infection, treatments used, drug resistance, treatment adherence or CD4 count, among others. Also, it is possible that increase of diabetes prevalence could reflect the improvement in recording habits.es_ES
dc.description.sponsorshipThis study forms part of research funded by the FIS (Fondo de Investigaciones Sanitarias—Health Research Fund, Instituto de Salud Carlos III grants no. PI13/00118, PI11/00245 & PI14CIII/00011 and PI12/00019) co-financed by the European Union through the Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”) and by the Grupo de Excelencia Investigadora URJC-Banco Santander Nº30VCPIGI03: Investigación traslacional en el proceso de salud—enfermedad (ITPSE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshComorbidity es_ES
dc.subject.meshDatabases, Factual es_ES
dc.subject.meshDiabetes Mellitus es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInpatients es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPrevalence es_ES
dc.subject.meshRetrospective Studies es_ES
dc.subject.meshSpain es_ES
dc.titleFifteen-Year Trends in the Prevalence of Diabetes among Hospitalized HIV-Infected Patients in Spain (1997-2012)es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID27589595es_ES
dc.format.volume11es_ES
dc.format.number9es_ES
dc.format.pagee0161953es_ES
dc.identifier.doi10.1371/journal.pone.0161953es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderBanco Santander 
dc.contributor.funderKing Juan Carlos University (España) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0161953es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/00118es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/00245es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI12/00019es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional